Get the StoQuant digest — free
Free StoQuant digest by email. No account needed.
See today's research picks.
GSK vs PRME — Stock Comparison
Compare GSK and PRME side-by-side on StoQuant: GSK Q-Score 50 vs PRME 50; analyst signal 55 vs 69. Plus alt data signals, insider buying, catalysts, strategic edges, short interest, social sentiment, and macro context.
Side-by-side snapshot
- GSK — GSK plc · Health Care · market cap $92.19B · Q-Score verdict Unrated (50.0) · analyst signal 55/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: technicals 24/100, analyst consensus 23/100 · weakest signals: ML forecast 8/100. Full GSK research.
- PRME — Prime Medicine Inc. Common Stock · Health Care · market cap $685M · Q-Score verdict Hold (50.0, grade C) · analyst signal 69/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: competitive moat 94/100, analyst consensus 76/100 · weakest signals: technicals 12/100. Full PRME research.
What you can compare
- Q-Score: StoQuant's composite 0–100 rating based on 140+ financial signals.
- Alt data signals: Google Trends, EDGAR 8-K filings, job postings, and more.
- Insider activity: Cluster scores and recent Form 4 buying.
- Catalysts: Earnings, analyst changes, M&A, clinical trials, and SEC events.
- Strategic edges: Competitive moat and durable advantage analysis.
- Short interest & social sentiment: Short % float, social mention volume, and bullish/bearish breakdown.
- Macro context: Market regime and sector rotation alignment.
Deep dive: GSK research · PRME research. Sign in to StoQuant to run live comparisons for any tickers. Sign up free →